Posted on the MS Trust website
25 May 2010 - Bioworld
Biogen Idec Inc and Abbott kicked off a Phase III trial comparing their anti-IL-2 antibody daclizumab to Biogen's Avonex (interferon beta-1a) in relapsing-remitting multiple sclerosis.
The trial initiation triggered a $30 million milestone payment from Biogen to Abbott. For full article click here